Teva Pharmaceutical Industries (TEVA) EBT (2016 - 2026)

Teva Pharmaceutical Industries' EBT history runs 11 years deep, the most recent figure standing at $437.0 million for Q1 2026.

• Quarterly EBT rose 48.64% year-over-year to $437.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 billion (up 361.19% YoY) and the FY2025 annual result came in at $1.2 billion, up 195.25% from the prior year.
• EBT was $437.0 million for Q1 2026 at Teva Pharmaceutical Industries, up from $80.0 million in the prior quarter.
• Across five years, EBT topped out at $646.0 million in Q3 2025 and bottomed at -$1.8 billion in Q4 2023.
• A 5-year average of -$278.8 million and a median of -$246.0 million in 2024 frame the typical range for EBT.
• Annual changes were most pronounced in 2022 — EBT plunged 774.31% — and 2025, when it surged 299.38%.
• Teva Pharmaceutical Industries' EBT stood at -$1.2 billion in 2022, then slumped by 48.1% to -$1.8 billion in 2023, then jumped by 85.93% to -$247.0 million in 2024, then jumped by 132.39% to $80.0 million in 2025, then surged by 446.25% to $437.0 million in 2026.
• Business Quant data shows TEVA's EBT at $437.0 million in Q1 2026, $80.0 million in Q4 2025, and $646.0 million in Q3 2025.